Education
About Us
Working with TipRanks
Follow Us
Senseonics Holdings Inc (SENS)
:SENS
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.02Last Year’s EPS
-0.03Same Quarter Last Year
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 03, 2025
|% Change Since: -24.14%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Neutral
The earnings call for Senseonics highlighted significant progress with the launch of the Eversense 365, resulting in increased patient adoption and prescriber growth. However, financial challenges remain, including flat revenue growth and increased net losses, with particular difficulties in the European market. Despite these challenges, the company's advancements in technology and strong partnerships indicate potential for future growth.Company Guidance
During the Senseonics earnings call for the fourth quarter and full year 2024, significant guidance was provided regarding the progress and future plans for Eversense 365, the first once-yearly continuous glucose monitor. The company reported a 56% increase in its patient base to approximately 6,000 global patients, surpassing its target growth of 50%. Additionally, there was a 73% increase in annual U.S. Eversense prescribers, reaching over 2,400, and direct-to-consumer leads increased by 40% compared to 2023. The company plans to launch Eversense 365 in Europe in the second half of 2025, pending CE Mark approval, and aims to double its global patient base in 2025. Financially, Senseonics expects full-year 2025 global net revenue to be between $34 million and $38 million, with gross margins projected to be between 25% and 30%. The company also anticipates cash utilization in 2025 to range from $50 million to $60 million. These metrics highlight the company's strategic focus on expanding its market presence and enhancing product offerings to improve patient experiences.Eversense 365 Launch Success
Since its launch in November 2024, the Eversense 365 has been well-received, with a 56% increase in the patient base to approximately 6,000 global patients and a 73% increase in annual US Eversense prescribers.
Positive Financial Outlook
Senseonics expects full-year 2025 global net revenue to be approximately $34 million to $38 million, with gross margins projected to be between 25% and 30%.
Technological Advancements
The pipeline programs Gemini and Freedom are progressing, with the Freedom system eliminating the need for an on-body transmitter.
Strong Partnerships
Senseonics continues to expand partnerships with health systems like Mercy and SweetSpot, increasing access to their CGM technology.
---
SENS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SENS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 03, 2025 | $0.87 | $0.70 | -19.54% |
| Nov 07, 2024 | $0.35 | $0.31 | -11.43% |
| Aug 08, 2024 | $0.40 | $0.38 | -5.00% |
| May 13, 2024 | $0.44 | $0.49 | +11.36% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Senseonics Holdings Inc (SENS) report earnings?
Senseonics Holdings Inc (SENS) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Senseonics Holdings Inc (SENS) earnings time?
Senseonics Holdings Inc (SENS) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SENS EPS forecast?
SENS EPS forecast for the fiscal quarter 2025 (Q1) is -0.02.
---